443
Participants
Start Date
October 31, 2005
Primary Completion Date
October 31, 2007
Study Completion Date
October 31, 2007
Arformoterol tartrate inhalation solution
Arformoterol 15 ųg BID by nebulization
Arformoterol 25 ųg BID
Arformoterol 25 ųg BID by nebulization
Formoterol 12 ųg BID
Formoterol fumarate 12 ųg BID via aerolizer/DPI
Placebo
Placebo nebule or placebo aerolizer
Statesville
Union
Atlanta
Gainesville
Bay Pines
St Louis
Medford
Birmingham
Jasper
Mobile
Little Rock
Carmichael
Fullerton
Long Beach
Paramount
Rancho Mirage
San Diego
Walnut Creek
Denver
Hartford
Brandon
Panama City
Tampa
Marietta
Normal
Evansville
Topeka
East Slidell
Lafayette
Metairie
Sunset
Baltimore
Chester
Wheaton
Ann Arbor
Saint Charles
St Louis
Albuquerque
Chapel Hill
Charlotte
Wilmington
Winston-Salem
Cincinnati
Lake Oswego
Pittsburgh
Swarthmore
East Providence
Charleston
Columbia
Simpsonville
Spartanburg
Knoxville
Houston
Katy
San Antonio
Danville
Richmond
Spokane
Tacoma
Morgantown
Sumitomo Pharma America, Inc.
INDUSTRY